Celvapan
influenza vaccine (H1N1)v (whole virion, Vero cell derived, inactivated)
Table of contents
Overview
The marketing authorisation for Celvapan has been withdrawn at the request of the marketing-authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Celvapan
|
| Agency product number |
EMEA/H/C/000982
|
| Active substance |
Whole virion influenza vaccine, inactivated containing antigen of strain A/California/07/2009 (H1N1)v
|
| International non-proprietary name (INN) or common name |
influenza vaccine (H1N1)v (whole virion, Vero cell derived, inactivated)
|
| Therapeutic area (MeSH) |
|
| Anatomical therapeutic chemical (ATC) code |
J07BB01
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Nanotherapeutics Bohumil, s.r.o.
|
| Revision |
11
|
| Date of issue of marketing authorisation valid throughout the European Union |
04/03/2009
|
| Contact address |
Bohumill38
28163 Jevany Czech Republic |
Product information
30/11/2015 Celvapan - EMEA/H/C/000982 - T/0031
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Vaccines
Therapeutic indication
Prophylaxis of influenza caused by A(H1N1)v 2009 virus.
Celvapan should be used in accordance with official guidance.